Short Report of Longitudinal CGRP-Measurements in Migraineurs During a Hypoxic Challenge.
CGRP
headache
hypoxia
longitudinal measurement
migraine
plasma levels
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
04
2022
accepted:
23
06
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Calcitonin gene related peptide (CGRP) plays a key role in the pathophysiology of migraine and is therefore considered a potential biomarker for primary headache disorders. The challenge remaining is establishing standardized protocols for its assessment in various extracellular compartments and identifying pathological situations associated with an increase in CGRP. We performed longitudinal measurements of CGRP plasma levels in 30 volunteers with the diagnosis of episodic migraine with and without aura under controlled circumstances during an induced migraine attack under a hypoxic challenge. Blood samples were collected from a cubital vein and CGRP plasma levels measured using ELISA. CGRP levels varied significantly between the subjects at baseline (15.48-1,889.31 pg/ml) but were neither associated with socio-demographic data nor with headache/migraine frequency or intensity collected before hypoxic exposure. CGRP levels during hypoxia fluctuated around baseline and increased with prolonged hypoxia but did not differ significantly in subjects with migraine or headache compared to those without. However, subjects experiencing migraine without aura showed significantly higher levels than those with aura. Ictal CGRP levels were increased in females, in subjects with a negative family history regarding headaches, in those older than 30 years of age or with a recent headache attack before the experiment ( CGRP plasma levels seem to be highly variable even at baseline in migraine patients and increased during hypoxic challenge and migraine attacks. This is the first in human longitudinal measurement of peripheral CGRP levels during induced migraine attacks using a highly standardized protocol.
Sections du résumé
Background
UNASSIGNED
Calcitonin gene related peptide (CGRP) plays a key role in the pathophysiology of migraine and is therefore considered a potential biomarker for primary headache disorders. The challenge remaining is establishing standardized protocols for its assessment in various extracellular compartments and identifying pathological situations associated with an increase in CGRP.
Methods
UNASSIGNED
We performed longitudinal measurements of CGRP plasma levels in 30 volunteers with the diagnosis of episodic migraine with and without aura under controlled circumstances during an induced migraine attack under a hypoxic challenge. Blood samples were collected from a cubital vein and CGRP plasma levels measured using ELISA.
Results
UNASSIGNED
CGRP levels varied significantly between the subjects at baseline (15.48-1,889.31 pg/ml) but were neither associated with socio-demographic data nor with headache/migraine frequency or intensity collected before hypoxic exposure. CGRP levels during hypoxia fluctuated around baseline and increased with prolonged hypoxia but did not differ significantly in subjects with migraine or headache compared to those without. However, subjects experiencing migraine without aura showed significantly higher levels than those with aura. Ictal CGRP levels were increased in females, in subjects with a negative family history regarding headaches, in those older than 30 years of age or with a recent headache attack before the experiment (
Conclusion
UNASSIGNED
CGRP plasma levels seem to be highly variable even at baseline in migraine patients and increased during hypoxic challenge and migraine attacks. This is the first in human longitudinal measurement of peripheral CGRP levels during induced migraine attacks using a highly standardized protocol.
Identifiants
pubmed: 35968307
doi: 10.3389/fneur.2022.925748
pmc: PMC9367467
doi:
Types de publication
Journal Article
Langues
eng
Pagination
925748Informations de copyright
Copyright © 2022 Frank, Kaltseis, Messlinger and Broessner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Neurology. 1991 Oct;41(10):1668-9
pubmed: 1922814
Curr Opin Neurol. 2017 Jun;30(3):281-286
pubmed: 28234796
Cephalalgia. 1995 Oct;15(5):384-90
pubmed: 8536297
Headache. 2017 May;57 Suppl 2:47-55
pubmed: 28485848
Shanghai Arch Psychiatry. 2014 Apr;26(2):105-9
pubmed: 25092958
Cephalalgia. 2020 Dec;40(14):1561-1573
pubmed: 32791920
Cephalalgia. 2016 Jul;36(8):765-71
pubmed: 26487467
J Headache Pain. 2018 Mar 12;19(1):22
pubmed: 29532195
Neurol Sci. 2018 Jul;39(7):1217-1223
pubmed: 29654418
Cephalalgia. 2019 Oct;39(12):1535-1543
pubmed: 31603037
Cephalalgia. 2006 Jul;26(7):816-9
pubmed: 16776696
Ann Neurol. 1990 Aug;28(2):183-7
pubmed: 1699472
Pain. 2000 May;86(1-2):133-8
pubmed: 10779670
Stroke. 2009 Jun;40(6):2205-8
pubmed: 19359638
Headache. 2006 Jan;46(1):24-33
pubmed: 16412148
J Headache Pain. 2018 Jul 13;19(1):53
pubmed: 30006780
Physiol Rev. 2014 Oct;94(4):1099-142
pubmed: 25287861
J Headache Pain. 2021 Sep 8;22(1):105
pubmed: 34496764
Pain. 2017 Apr;158(4):543-559
pubmed: 28301400
Headache. 2016 Jan;56(1):12-35
pubmed: 26639834
Brain. 2016 Mar;139(Pt 3):723-37
pubmed: 26674653
Neurology. 2013 Oct 1;81(14):1191-6
pubmed: 23975872
Nat Neurosci. 2007 Jun;10(6):754-62
pubmed: 17468748
Cephalalgia. 2021 Nov;41(13):1359-1373
pubmed: 34266288
Cephalalgia. 2019 Mar;39(3):435-444
pubmed: 29082826
Cephalalgia. 2019 Mar;39(3):333-341
pubmed: 27919019